[Retracted] Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC

Table 1

Comparison of clinical data between two groups (‾x ± s).

Indicators		Control group (n = 54)	Observation group (n = 46)	t/χ^2	value
Age		61.68 ± 5.46	62.74 ± 6.12	0.915	0.362
Gender	Male	32 (59.26%)	25 (54.35%)	0.245	0.621
	Female	22 (40.74%)	21 (45.65%)
BMI		22.01 ± 1.08	21.74 ± 1.41	1.083	0.281
Pathological type	Adenocarcinoma	28 (51.85%)	22 (47.83%)	0.404	0.817
	Squamous carcinoma	21 (38.89%)	18 (39.13%)
	Squamous adenocarcinoma	5 (9.26%)	6 (13.04%)
Clinical stage	IIIa	6 (11.11%)	8 (17.40%)	0.881	0.643
	IIIb	29 (53.70%)	24 (52.17%)
	IV	19 (35.19%)	14 (30.43%)